WEKO3
アイテム
体内老化細胞を検出・除去する放射性薬剤の開発
https://repo.qst.go.jp/records/2002328
https://repo.qst.go.jp/records/2002328381725b3-ea5c-4241-a093-70aa984ceaaf
| アイテムタイプ | 会議発表用資料 / Presentation(1) | |||||||
|---|---|---|---|---|---|---|---|---|
| 公開日 | 2025-08-25 | |||||||
| タイトル | ||||||||
| タイトル | 体内老化細胞を検出・除去する放射性薬剤の開発 | |||||||
| 言語 | en | |||||||
| 言語 | ||||||||
| 言語 | eng | |||||||
| 資源タイプ | ||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||||
| 資源タイプ | conference presentation | |||||||
| 著者 |
Zhang Ming-Rong
× Zhang Ming-Rong
|
|||||||
| 抄録 | ||||||||
| 内容記述 | Inhibiting glutamine metabolism has been proposed as a potential treatment strategy forimproving non-alcoholic steatohepatitis (NASH). However, effective methods for assessing dynamicmetabolic responses during interventions targeting glutaminolysis have not yet emerged. Here, we developeda positron emission tomography (PET) imaging platform using L-[5-11C]glutamine ([11C]Gln) andevaluated its efficacy in NASH mice undergoing metabolic therapy with bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES), a glutaminase 1 (GLS1) inhibitor that intervenes in the first andrate-limiting step of glutaminolysis. PET imaging with [11C]Gln effectively delineated the pharmacokineticsof L-glutamine, capturing its temporal-spatial pattern of action within the body. Furthermore, [11C]Gln PET imaging revealed a significant increase in hepatic uptake in methionine and choline deficient(MCD)-fed NASH mice, whereas systemic therapeutic interventions with BPTES reduced the hepaticavidity of [11C]Gln in MCD-fed mice. This reduction in [11C]Gln uptake correlated with a decrease in GLS1 burden and improvements in liver damage, indicating the efficacy of BPTES in mitigating NASHrelatedmetabolic abnormalities. These results suggest that [11C]Gln PET imaging can serve as a noninvasivediagnostic platform for whole-body, real-time tracking of responses of glutaminolysis to GLS1manipulation in NASH, and it may be a valuable tool for the clinical management of patients with NASHundergoing glutaminolysis-based metabolic therapy. | |||||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||||
| 内容記述 | Linyi International Symposium on Nuclear Medicine and Molecular Imaging 2024 | |||||||
| 発表年月日 | ||||||||
| 日付 | 2025-09-12 | |||||||
